Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Tetrylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrylammonium SCHEMBL36703 | 0.90 | TSHR (0.57) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL331297 | 0.87 | TSHR (0.53) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL28602156 | 0.87 | TSHR (0.53) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL3643964 | 0.87 | TSHR (0.53) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL621848 | 0.87 | TSHR (0.53) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL36660 | 0.84 | TSHR (0.50) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL14118730 | 0.84 | TSHR (0.50) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL36705 | 0.84 | TSHR (0.50) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL36659 | 0.84 | TSHR (0.50) | TSHRNFKB1KCNA1KDM4EPMP22 | |
| Tetrylammonium SCHEMBL7638063 | 0.84 | TSHR (0.50) | TSHRNFKB1KCNA1KDM4EPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015560-A1 | COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES | ENTEGRIS INC (US) | 2026-01-15 | — | — | US | claimed |
| EP-2294135-B1 | FLAME RETARDANT, OPTICALLY CLEAR THERMOPLASTIC MOLDING COMPOSITION | COVESTRO LLC (US) | 2017-07-26 | — | — | EP | claimed |
| EP-2480608-B1 | FLAME RETARDANT, OPTICALLY CLEAR THERMOPLASTIC MOLDING COMPOSITION | COVESTRO LLC (US) | 2017-05-24 | — | — | EP | claimed |
| EP-1702005-B1 | POLYCARBONATE COMPOSITION | GEN ELECTRIC (US) | 2007-07-25 | — | — | EP | claimed |
| CN-122079810-A | Aromatic diamine and polyimide containing amido, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260015560-A1 | COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES | ENTEGRIS INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4649083-A1 | COMPOUNDS DERIVED FROM DIHYDROPIRIDINES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS AND METHOD OF TREATMENT OF MUSCLE DISORDERS COMPRISING ADMINISTRATION OF SAID COMPOSITIONS | Universidad de Chile (CL) | 2025-11-19 | — | — | EP | disclosed |
| US-20250049953-A1 | TREATMENT AND METHOD FOR INHIBITING LATE NA CURRENT | UNIV COLUMBIA (US) | 2025-02-13 | — | — | US | disclosed |
| CN-119020330-A | Compositions and methods for detecting ubiquitin-dependent cellular processes using engineered deubiquitinase | 纽约市哥伦比亚大学理事会 | 2024-11-26 | — | — | CN | disclosed |
| CN-118995678-A | Compositions and methods for detecting ubiquitin-dependent cellular processes using engineered deubiquitinase | 纽约市哥伦比亚大学理事会 | 2024-11-22 | — | — | CN | disclosed |
| CN-118834857-A | Compositions and methods for detecting ubiquitin-dependent cellular processes using engineered deubiquitinase | 纽约市哥伦比亚大学理事会 | 2024-10-25 | — | — | CN | disclosed |
| CN-111787940-B | Compositions and methods for detecting ubiquitin-dependent cellular processes using engineered deubiquitinase | 纽约市哥伦比亚大学理事会 | 2024-09-10 | — | — | CN | disclosed |
| US-7833643-B2 | Neutral protic-salt electrolytes and protic-salt imbibed polymer membranes for high temperature fuel cell applications | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2010-11-16 | — | — | US | disclosed |
| US-20070122675-A1 | Neutral Protic-Salt Electrolytes and Protic-Salt Imbibed Polymer Membranes for High Temperature Fuel Cell Applications | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2007-05-31 | — | — | US | disclosed |
| EP-0433806-B1 | Isocyanatoalkylsulfonates and process for their preparation | BAYER AG (DE) | 1994-06-22 | — | — | EP | disclosed |
| EP-0412359-B1 | Method for the preparation of epoxysulphonates | BAYER AG (DE) | 1994-06-08 | — | — | EP | disclosed |
| US-5110975-A | ISOCYANATOALKYL SULPHONATES AND A PROCESS FOR THEIR PREPARATION | BAYER AKTIENGESELLSCHAFT (DE) | 1992-05-05 | — | — | US | disclosed |
| EP-0433806-A2 | Isocyanatoalkylsulfonates and process for their preparation | BAYER AG (DE) | 1991-06-26 | — | — | EP | disclosed |
| EP-0412359-A1 | Method for the preparation of epoxysulphonates | BAYER AG (DE) | 1991-02-13 | — | — | EP | disclosed |
| US-4225498-A | Preparation of N-substituted oligo-imides | RHONE-POULENC INDUSTRIES (FR) | 1980-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015560-A1 | COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES | TET2, ASIC1, PIEZO1 | SLC6A4 1219/4885TSHR 2647/4885NFKB1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.